Retraction to: MicroRNA-495 mimics delivery inhibits lung tumor progression (Tumor Biology, (2015), 36, 2, (729-735), 10.1007/s13277-014-2687-1);MicroRNA-495 mimics delivery inhibits lung tumor progression

Tumor Biology

Volumn 36, Issue 2, 2015, Pages 729-735

  Ai, Cheng ^a   Jiang, Rujian ^a   Fu, Li ^a   Chen, Youdong ^a  

^a Sichuan Province Panzhihua Central Hospital   (China)

Author keywords

Cancer therapy; Lung cancer; miR 495; Systematic delivery

Indexed keywords

LIPID EMULSION; MICRORNA; MICRORNA 495; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; MIRN495 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPOSOMAL GENE DELIVERY SYSTEM; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; SINGLE DRUG DOSE; SYSTEMIC THERAPY; TRANSGENIC MOUSE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DISEASE COURSE; DRUG SCREENING; GENE TRANSFER; GENETICS; LUNG NEOPLASMS; PATHOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; GENE TRANSFER TECHNIQUES; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG NEOPLASMS; MICE; MICRORNAS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925464780     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-5471-6     Document Type: Erratum

References (21)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics. CA Cancer J Clin. 2008;58:71–96,2008.
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.
3. Baranwal S, Alahari SK. miRNA control of tumor cell invasion and metastasis. Int J Cancer. 2010;126:1283–90.
4. Iorio MVCroce CM. microRNA involvement in human cancer. Carcinogene. 2012.
5. Jiang X, Huang H, Li Z, He C, Li Y, Chen P, et al. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia. Proc Natl Acad Sci U S A. 2012;109:19397–402.
6. Chen SM, Chen HC, Chen SJ, Huang CY, Chen PY, Wu TW, et al. MicroRNA-495 inhibits proliferation of glioblastoma multiforme cells by downregulating cyclin-dependent kinase 6. World J Surg Oncol. 2013;11:87.
7. Li Z, Cao Y, Jie Z, Liu Y, Li Y, Li J, et al. miR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3. Cancer Lett. 2012;323:41–7.
8. Bader AG, Brown D, Winkler M. The promise of microRNA replacement therapy. Cancer Res. 2010;70:7027–30.
9. McCormick F. Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer. 2001;1:130–41.
10. Roth JA. Adenovirus p53 gene therapy. Expert Opin Biol Ther. 2006;6:55–61.
11. Melo SA, Ropero S, Moutinho C, Aaltonen LA, Yamamoto H, Calin GA, et al. A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet. 2009;41:365–70.
12. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010;70:5923–30.
13. Zhang Y, Liu D, Chen X, Li J, Li L, Bian Z, et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell. 2010;39:133–44.
14. Brown RH, Walters DM, Greenberg RS, Mitzner W. A method of endotracheal intubation and pulmonary functional assessment for repeated studies in mice. J Appl Physiol. 1985;87:2362–5,1999.
15. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001;15:3243–8.
16. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle. 2008;7:759–64.
17. Landen Jr CN, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005;65:6910–8.
18. Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer. 2007;6:60.
19. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103:2257–61.
20. Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D, et al. Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol. 2009;24:652–7.
21. Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K, Mori M. Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res. 2008;14:2334–40.